

- cytic leukaemia. *Haematologica* 1999; 84:64-6.
21. Havouis S, Dumas G, Ave P, Pritsch O, Huerre M, Dighiero G, Pourcel C. A murine transgenic model of human cold agglutinin disease. *Haematologica* 1999; 84:67-9.
 22. Minucci S, Ciocce M, Maccarana M, Pelicci PG. The APL-associated fusion proteins. *Haematologica* 1999; 84:70-1.
 23. Lo Coco F, Diverio D, Avvisati G, Mandelli F. Diagnosis, front line treatment and molecular monitoring of acute promyelocytic leukaemia. *Haematologica* 1999; 84:72-4.
 24. Warrell RP Jr. Arsenicals and inhibitors of histone deacetylase as anticancer therapy. *Haematologica* 1999; 84:75-7.
 25. Sanson BJ, Meinders AJ, Kraaijenhagen RA, van Beek EJ, Buller HR. Requirements for appropriate evaluation of diagnostic tests in suspected pulmonary embolism. *Haematologica* 1999; 84:78-81.
 26. Agnelli G. Clinical significance of non clinical endpoints in studies on the prevention of venous thromboembolism. *Haematologica* 1999; 84:82-4.
 27. ten Cate JW, Buller HR. Randomised evaluation of treatment modalities in thromboembolic disorders. *Haematologica* 1999; 84:85-7.
 28. Oscier DG. Cytogenetics and molecular genetics of chronic lymphocytic leukaemia. *Haematologica* 1999; 84:88-91.
 29. Catovsky D. Morphology, atypical chronic lymphocytic leukaemia and prognostic features affecting choice of therapy. *Haematologica* 1999; 84:92-3.
 30. Rai KR. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment. *Haematologica* 1999; 84:94-5.
 31. Binet JL. Prognostic factors in chronic lymphocytic leukaemia. *Haematologica* 1999; 84:96-7.
 32. Mecucci C, Falzetti D, La Starza R. Metaphase FISH, microdissection, and multicolour FISH. Applications in haematology. *Haematologica* 1999; 84:98-101.
 33. Bentz M, Stilgenbauer S, Lichter P, Dohner H. Interphase FISH in chronic lymphoproliferative disorders and comparative genomic hybridisation in the study of lymphomas. *Haematologica* 1999; 84:102-6.
 34. Gabert J. Detection of recurrent translocations using real time PCR: assessment of the technique for diagnosis and detection of minimal residual disease. *Haematologica* 1999; 84:107-9.
 35. Murphy MF, Manley R, Roberts D. Neonatal alloimmune thrombocytopenia. *Haematologica* 1999; 84:110-4.
 36. Rivera J, Vicente V. Potential and current development of platelet products. *Haematologica* 1999; 84:115-9.
 37. Cattaneo M, Mannucci PM. Current status of non-transfusional haemostatic agents. *Haematologica* 1999; 84:120-3.
 38. Masera G. Geographic hematology: an evolving concept. *Haematologica* 2000; 85: 785-6.

Haematologica's impact factor

The journal's 1999 Impact Factor (JCR® - 1999 Science Edition, ISI, Philadelphia, USA) is equal to 2.074. Since the early '90s, with one exception, the journal's Impact Factor has constantly increased (Figure 1).

How was 2.074 obtained? *Haematologica* has published 149 articles in 1997 and 149 articles in 1998. Cites in 1999 to articles published in 1997 and 1998 have proved to be 618 (ISI data). 2.074 is the ratio between 618 and 298 (149+149).

The Ferrata Storti Foundation – journal's owner – wishes to thank all the scientists who have contributed to the *Haematologica*'s growth: authors, editors and reviewers (in alphabetical order...).

Mario Cazzola, M.D.
Executive Editor, *Haematologica*
m.cazzola@haematologica.it




Figure 1. Time course of *Haematologica*'s impact factor and of the total number of pages published per year.